The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acceleron Pharma Inc. | COM | 00434H108 | 12,224 | 108,630 | SH | SOLE | 108,630 | 0 | 0 | ||
| Aclaris Therapeutics, Inc. | COM | 00461U105 | 1,760 | 684,912 | SH | SOLE | 684,912 | 0 | 0 | ||
| Cymabay Therapeutics, Inc. | COM | 23257D103 | 11,887 | 1,641,804 | SH | SOLE | 1,641,804 | 0 | 0 | ||
| Epizyme, Inc. | COM | 29428V104 | 11,909 | 998,278 | SH | SOLE | 998,278 | 0 | 0 | ||
| FibroGen, Inc. | COM | 31572Q808 | 7,093 | 172,500 | SH | SOLE | 172,500 | 0 | 0 | ||
| Myokardia, Inc. | COM | 62857M105 | 54,445 | 399,360 | SH | SOLE | 399,360 | 0 | 0 | ||
| Natera, Inc. | COM | 632307104 | 15,081 | 208,768 | SH | SOLE | 208,768 | 0 | 0 | ||
| Novavax, Inc. | COM | 670002401 | 542 | 5,000 | SH | SOLE | 5,000 | 0 | 0 | ||
| Oric Pharmaceuticals, Inc. | COM | 06822P109 | 12,427 | 496,893 | SH | SOLE | 496,893 | 0 | 0 | ||
| Verona Pharma plc | SPONS ADS | 925050106 | 6,933 | 1,111,112 | SH | SOLE | 1,111,112 | 0 | 0 | ||